Stockwatch: Investors struggle with United front for FREEDOM
This article was originally published in Scrip
In a month where investors have seen wide gyrations in share prices as the markets expect the first, but maybe not the last, European sovereign debt default, one biotechnology company, United Therapeutics,seems to have generated its own additional volatility but for all the wrong reasons. On 24 August, United reported the results of its Freedom-C2 Phase III clinical study for the drug oral treprostinil for pulmonary hypertension (PAH) (scripintelligence.com , 25 August 2011,). The study failed to meet the primary endpoint in the six-minute walk test (6-MW) compared to placebo and the share price of United finished the week down just under 20% against the Nasdaq Biotech Index (of which, United is a significant component) which finished the week with a slight gain.
You may also be interested in...
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
Following Mylan’s first-quarter 2020 earnings announcement, all the biggest generic pharmaceutical companies have now reported. Concerns about supply chain disruptions in March have proven to have been overblown and guidance has largely been reaffirmed. So, are generics immune from coronavirus?